Ginkgo Bioworks Holdings Class A (DNA) closed at $11.65 on November 4, 2026, up 8.3% from the previous close, on volume of 2,535,640 shares (30-day average 3,224,756).
Data as of November 4, 2026.
Ginkgo Bioworks (DNA) Brings Its 70+ Instrument Cloud Lab to NSF’s $1.5 Billion X-Labs Program
Market Chameleon (Fri, 9-Oct 3:07 AM ET)
Business Wire (Thu, 8-Oct 4:10 PM ET)
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
PRNewswire (Thu, 8-Oct 6:01 AM ET)
Business Wire (Tue, 29-Sep 8:08 AM ET)
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
Business Wire (Wed, 16-Sep 9:52 AM ET)
Business Wire (Thu, 10-Sep 8:00 AM ET)
Ginkgo Bioworks Doubles Down on Autonomous Lab Ambition After Divesting Biosecurity Business
Market Chameleon (Fri, 8-May 3:08 AM ET)
Market Chameleon (Fri, 6-Feb 2:06 AM ET)
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Ginkgo Bioworks Holdings Class A trades on the NYSE stock market under the symbol DNA.
As of November 5, 2026, DNA stock price declined to $10.63 with 121,882 million shares trading.
DNA has a beta of 2.83, meaning it tends to be more sensitive to market movements. DNA has a correlation of 0.13 to the broad based SPY ETF.
DNA has a market cap of $715.83 million. This is considered a Small Cap stock.
Last quarter Ginkgo Bioworks Holdings Class A reported $20 million in Revenue and -$.92 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.22.
In the last 3 years, DNA traded as high as $75.20 and as low as $5.00.
The top ETF exchange traded funds that DNA belongs to (by Net Assets): VTI, IWM, VXF, IWN, THNQ.
DNA has underperformed the market in the last year with a return of -8.3%, while SPY returned +13.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DNA shares. However, DNA has outperformed the market in the last 3 month and 2 week periods, returning +13.4% and +6.2%, while SPY returned -1.4% and -1.9%, respectively. This indicates DNA has been having a stronger performance recently.
DNA support price is $10.73 and resistance is $12.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNA shares will trade within this expected range on the day.
